Gout is a common and excruciatingly painful inflammatory arthritis associated with hyperuricemia. Gout represents a metabolically-driven arthropathy that could be substantially controlled through dietary and lifestyle modifications. With the continued """"""""western"""""""" lifestyle in the US, the prevalence and incidence of gout have increased over the last few decades and it is estimated that 3.9% of US adults (8.3 million individuals) have had gout according to the latest US NHANES data. This remarkable burden of gout is further complicated by its high level of cardiovascular (CV)-metabolic comorbidities (e.g., hypertension in 74% and obesity in 53% of cases) and their consequences (e.g., increased future risk of myocardial infarction and premature death). The current low-purine dietary approach to gout offers limited efficacy, palatability, and sustainability, and promotes increased consumption of refined carbohydrates and saturated fat that can actually worsen gout's CV-metabolic comorbidities by leading to insulin-resistance and increased levels of plasma glucose, triglycerides, and LDL-cholesterol. Therefore, there is an urgent need for a unifying, sustainable, and effective prevention strategy that holistically addresses both gout and its associated comorbidities. In fact, there are proven, effective dietary approaches to reduce CV-metabolic conditions (including obesity) that could also lower serum uric acid (SUA) levels and the risk of gout by lowering adiposity and insulin resistance. These existing approaches could potentially provide an ideal dietary strategy to reduce both the risk of gout and its associated CV-metabolic conditions. In this study, we will build upon our extensive experience with gout prevention research to examine the impact of these dietary approaches on the outcomes of both SUA and gout. We will investigate their effects on SUA levels using stored blood samples from 6 landmark randomized controlled trials of various dietary approaches to reduce CV-metabolic conditions (including the Mediterranean, Atkins, and DASH diets) (Aims 1-3). Through participation of the PIs of all 6 trials in this project, we will take full advantage of the originl RCT designs and collected data. Further, we will evaluate their impact on the risk of gout based on 3 large prospective cohorts: the Nurses'Health Study (NHS) I (n=121,700 women), NHS II (n=116,430 younger women), and the Health Professionals Follow-up Study (HPFS;n=51,529 men) (Aim 4). We will take advantage of systematically collected high- quality data that have undergone rigorous validation including >3,200 confirmed cases of incident gout.
These aims hold the potential to revolutionize our non-pharmacological urate-lowering approaches to hyperuricemia and gout by simultaneously investigating multiple candidate diets using a highly cost-effective study design. These measures will also comprehensibly address the major comorbidities associated with the rising disease burden of gout. With our extensive gout research experience combined with resourceful data access, we are in a unique and unparalleled position to address these key issues facing the field in the US and beyond.
There is a remarkable, increasing disease burden of gout and its associated cardiovascular-metabolic comorbidities in the US, underscoring an urgent need for holistic strategies to effectively address these conditions. The current project will address this need by simultaneously investigating multiple candidate diets using a highly cost-effective study design. This proposal holds the potential to revolutionize non- pharmacological urate-lowering approaches to gout and will substantially contribute to the goal of reducing the disease burden of both gout and associated comorbidities in the US and beyond.
|Jorge, April M; Lu, Na; Zhang, Yuqing et al. (2018) Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). Rheumatology (Oxford) 57:337-344|
|Rai, Sharan K; Choi, Hyon K; Choi, Sally H J et al. (2018) Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology (Oxford) :|
|Keller, Sarah F; Rai, Sharan K; Lu, Na et al. (2018) Statin use and mortality in gout: A general population-based cohort study. Semin Arthritis Rheum 48:449-455|
|Keller, Sarah F; Lu, Na; Blumenthal, Kimberly G et al. (2018) Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study. Ann Rheum Dis 77:1187-1193|
|Tang, Olive; Miller 3rd, Edgar R; Gelber, Allan C et al. (2017) DASH diet and change in serum uric acid over time. Clin Rheumatol 36:1413-1417|
|Rai, Sharan K; Aviña-Zubieta, J Antonio; McCormick, Natalie et al. (2017) The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Semin Arthritis Rheum 46:451-456|
|Jutkowitz, Eric; Dubreuil, Maureen; Lu, Na et al. (2017) The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum 46:594-600|
|Rai, Sharan K; Aviña-Zubieta, J Antonio; McCormick, Natalie et al. (2017) Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011. Arthritis Care Res (Hoboken) 69:758-762|
|Dalbeth, Nicola; Choi, Hyon K; Terkeltaub, Robert (2017) Review: Gout: A Roadmap to Approaches for Improving Global Outcomes. Arthritis Rheumatol 69:22-34|
|Dalbeth, Nicola; Bardin, Thomas; Doherty, Michael et al. (2017) Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol 13:561-568|
Showing the most recent 10 out of 25 publications